MedTrace Logo

Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients

NCT05478018 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-09-09

No results posted yet for this study

Summary

Investigating the physiological effects of the interferons type 1 and 2 (IFNs), and the cytokines Interleukin 6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with systemic lupus erythematosus (SLE).

The investigators hypothesize that the pathogenic blockage of IL-6 signalling that occurs in SLE, will decrease the cardiac and metabolic adaptations to aerobic exercise, and this decrease can be related to the IFN signature.

55 patients was included in a 12-week investigator blinded 1:1 randomised high intensity aerobic exercise intervention study.

Conditions

Interventions

BEHAVIORAL

High Intensity Interval Training (HIIT)

Supervised high-intensity interval training for 12 weeks three times per week

Sponsors & Collaborators

  • Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet

    collaborator UNKNOWN

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Ronan Martin G Berg, MD, DMSc · Center for Physical Activity Research

  • Iben E Rasmussen, MSc · Center for Physical Activity Research

  • Simon Jønck, MD · Center for Physical Activity Research

  • Malte L Adamsen, MD · Center for Physical Activity Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-04-16
Completion
2025-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05478018 on ClinicalTrials.gov